| Literature DB >> 19204960 |
Steven V Ley1, Miles N Tackett, Matthew L Maddess, James C Anderson, Paul E Brennan, Michael W Cappi, Jag P Heer, Céline Helgen, Masakuni Kori, Cyrille Kouklovsky, Stephen P Marsden, Joanne Norman, David P Osborn, María A Palomero, John B J Pavey, Catherine Pinel, Lesley A Robinson, Jürgen Schnaubelt, James S Scott, Christopher D Spilling, Hidenori Watanabe, Kieron E Wesson, Michael C Willis.
Abstract
For over 30 years, rapamycin has generated a sustained and intense interest from the scientific community as a result of its exceptional pharmacological properties and challenging structural features. In addition to its well known therapeutic value as a potent immunosuppressive agent, rapamycin and its derivatives have recently gained prominence for the treatment of a wide variety of other human malignancies. Herein we disclose full details of our extensive investigation into the synthesis of rapamycin that culminated in a new and convergent preparation featuring a macro-etherification/catechol-templating strategy for construction of the macrocyclic core of this natural product.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19204960 DOI: 10.1002/chem.200801656
Source DB: PubMed Journal: Chemistry ISSN: 0947-6539 Impact factor: 5.236